<DOC>
	<DOCNO>NCT02035488</DOCNO>
	<brief_summary>Bronchiectasis persistent frequently progressive condition characterize dilate thick-walled bronchus retain sputum . The main symptom bronchiectasis cough chronic sputum production . Until , patient non-CF bronchiectasis receive inhale tobramycin every month , use nebulizer . However , delivery system several disadvantage , like low lung deposition pollution tobramycin surround environment . With efficient dry powder inhaler ( DPI ) , three six fold high lung deposition compare nebulizer obtain . Therapy DPI also less time consume compare nebulisation . We investigate dry powder tobramycin ( DP tobramycin ) novel device patient non-CF bronchiectasis . The main objective study investigate pharmacokinetic property DP tobramycin different dosage together local tolerability DP tobramycin via Cyclops® different dosage .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Tolerability Dry Powder Tobramycin Novel Device Patients With Non Cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description>Rationale : Bronchiectasis persistent frequently progressive condition characterize dilate thick-walled bronchus retain sputum . The main symptom bronchiectasis cough chronic sputum production . There state constant colonization bacteria , frequently cause exacerbation . The presence Pseudomonas aeruginosa unfavorable prognostic indicator associate increase sputum production , extensive bronchiectasis HR-CT thorax , hospitalization reduce quality life . Until , patient non-CF bronchiectasis colonize P. aeruginosa receive inhale tobramycin every month , use nebulizer . However , delivery system several disadvantage , like low lung deposition pollution tobramycin surround environment . With efficient dry powder inhaler ( DPI ) , three six fold high lung deposition compare nebulizer obtain . Therapy DPI also less time consume compare nebulisation . Nebulised tobramycin use routine care ; also one , rather poorly characterize DPI tobramycin available , though DPI registrered non-CF bronchiectasis . We investigate dry powder tobramycin ( DP tobramycin ) novel device patient non-CF bronchiectasis colonize P. aeruginosa . Objective : The main objective investigate pharmacokinetic property DP tobramycin different dosage together local tolerability DP tobramycin via Cyclops® different dosage . Study design : single center , single ascending , single dose , response study . Study population : 8 patient non-CF bronchiectasis Main study parameter : The following pharmacokinetic parameter calculate : actual dose ( dose minus remainder inhaler inhalation ) , AUC0-12 ( area curve 0 -12 h ) , Cmax ( maximum plasma concentration ) , Tmax ( time maximum plasma concentration ) , Ka ( absorption rate constant ) , T1/2 el ( terminal elimination half-life ) , CL/F ( clearance follow pulmonary administration ( F= bioavailability ) ) . Local tolerability DP tobramycin determine score adverse event , specifically cough , lung function measurement . Nature extent burden risk associate participation , benefit group relatedness : All participant include study patient recruit outpatient department pulmonology . To investigate safety , lung function test perform occurrence adverse event score .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Inclusion criterion : Age 18 year old Obtained informed consent Patients bronchiectasis ( confirm HRCT chest ) Exclusion criterion : Pregnant breast feeding Subjects know suspected renal , auditory , vestibular neuromuscular dysfunction , severe , active haemoptysis , History adverse event previous tobramycin aminoglycoside use No concurrent use cyclosporin , cisplatin , amfotericin B , cephalosporins , polymyxin , vancomycin NSAIDs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Dry powder inhalation</keyword>
	<keyword>Bronchiectasis</keyword>
	<keyword>Tobramycin</keyword>
</DOC>